Aimmune Therapeutics
8000 Marina Boulevard
Suite 200
Brisbane
California
94005-1884
United States
About Aimmune Therapeutics
191 articles about Aimmune Therapeutics
-
Aimmune Reports Positive Findings For ARC002 Follow-On Phase II Study Of AR101 For Treatment Of Peanut Allergy
11/11/2015
-
Aimmune Announces Financial Results For The Third Quarter 2015
11/5/2015
-
Aimmune To Present At The 2015 Credit Suisse Healthcare Conference
11/2/2015
-
Aimmune Announces COO Transition
10/9/2015
-
Aimmune Receives European Medicines Agency Decision Agreeing With PIP For AR101 For The Treatment Of Peanut Allergy
10/7/2015
-
Aimmune To Present At The Bank of America Merrill Lynch Global Healthcare Conference
9/3/2015
-
Aimmune Reports Second Quarter 2015 Financial Results
9/1/2015
-
Aimmune Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
8/12/2015
-
NorCal's Aimmune Signs Lease for Huge Facility in Florida
8/11/2015
-
Aimmune Announces Pricing Of Initial Public Offering
8/6/2015
-
Bay Area's Global Blood Therapeutics, Aimmune Jump on the IPO Wagon Seeking $115 Million Each
7/13/2015